Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Betekom – page 107

1 978 clinical trials in Betekom, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Betekom at a glance
1 978
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 978 trials in Betekom

Open in trial search

Study of IDRX-42 for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Velzatinib
  • Sponsor:Idrx Inc.

Glioma

Not recruiting

Study of Abemaciclib and Temozolomide for Children and Young Adults with Newly Diagnosed High-Grade Glioma After Radiotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Diabetic retinopathy+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3283142
  • Sponsor:Bayer AG

Acute kidney injury

Not recruiting

Study on TIN816 for Preventing Acute Kidney Injury in Adults Undergoing Cardiac Surgery

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TIN816
  • Sponsor:Novartis Pharma AG

Prostate cancer

Not recruiting

Study Comparing Degarelix and Drug Combination with Radiotherapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Malignant melanoma

Not recruiting

Study on Ceralasertib and Durvalumab for Patients with Advanced Melanoma Resistant to PD-(L)1 Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Long-term Safety Study of Onasemnogene Abeparvovec for Patients with Spinal Muscular Atrophy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Onasemnogene Abeparvovec
  • Sponsor:Novartis Pharma AG

Uveal melanoma

Not recruiting

Study of Darovasertib and Crizotinib for Patients with Metastatic Uveal Melanoma Who Are HLA-A2 Negative

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Ideaya Biosciences Inc.

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:LYSARC

Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

HIV infection

Not recruiting

Study of IMC-M113V for Patients with Chronic HIV Infection Who Are Virologically Suppressed

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:IMC-M113V
  • Sponsor:Immunocore Limited

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Betekom

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on optimizing treatment strategies for patients with functional dyspepsia and related gastrointestinal conditions. This study explores effective methods for reducing long-term dependency on proton pump inhibitors (PPIs).

  • Medication De-prescribing Strategies
  • Gastrointestinal Health Management
  • Alternative Treatment Approaches

The research evaluates various therapeutic approaches, including on-demand medication use and alternative treatments, aiming to improve patient care in primary healthcare settings.

02 Primary Care Innovation

A groundbreaking study examining the effectiveness of different approaches to managing chronic acid reflux and heartburn symptoms. This research aims to establish more patient-centered treatment protocols.

  • Patient-Centered Care
  • Long-term Medication Management
  • Treatment Optimization

The trial explores innovative strategies to help patients safely reduce their dependence on long-term acid suppression therapy while maintaining symptom control.

03 Therapeutic Alternatives

Investigation into the comparative effectiveness of different treatment strategies for digestive disorders, including traditional medication tapering and alternative therapeutic approaches.

  • Medication Alternatives
  • Symptom Management
  • Quality of Life Impact

This research evaluates various therapeutic options, including alginate-based treatments, to provide evidence-based alternatives for long-term acid suppression therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.